Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: Three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals

Cancer

Volumn 114, Issue 2, 2008, Pages 134-140

  Itoh, Hitoshi ^a,b   Miyajima, Yoko ^a   Umemura, Shinobu ^a   Osamura, Robert Y ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cytology; Fluorescence in situ hybridization; HER 2; Paraffin embedded sections

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; BREAST DUCT; CANCER CYTODIAGNOSIS; CELL NUCLEUS MEMBRANE; CENTROMERE; CHROMOSOME ENUMERATION PROBE 17; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; DEVICE; DIAGNOSTIC ACCURACY; DNA PROBE; DUCTAL BREAST CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; INVASIVE CARCINOMA; MOLECULAR PROBE; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE NEU; PRIORITY JOURNAL; RELIABILITY; SIGNAL TRANSDUCTION; THREE DIMENSIONAL IMAGING;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL NUCLEUS; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; DNA PROBES; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 43149108641     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23367     Document Type: Article

References (20)

1. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
3. Kakar S, Puangsuvan N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000;5:199-207.
4. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
6. Gu M, Ghafari S, Zhao M. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol. 2005;49:471-476.
7. Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol. 2004;122:246-255.
8. Moore JG, To V, Patel SJ, et al. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections. Diagn Cytopathol. 2000;23:299-302.
9. Nizzoli R, Guazzi A, Naldi N, et al. HER-2/neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer. Acta Cytol. 2005;49:27-30.
10. Bozzetti C, Personeni N, Nizzoli R, et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (Cancer Cytopathol). 2003;99:310-315.
11. Mezzelani A, Alasio L, Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer. 1999;80:519-525.
12. Klijanienko J, Couturier J, Galut M, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer (Cancer Cytopathol). 1999;87:312-318.
13. Bofin AM, Ytterhus B, Martin C, et al. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol. 2004;122:110-119.
14. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
15. McCormick SR, Lillemoe TJ, Beneke J, et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002;117:935-943.
16. Bose S, Mohammed M, Shintaku P, et al. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/HER-2/NEU polysomy. Breast. J. 2001;7:337-344.
17. Wang S, Hossein Saboorian M, Frenkel ER et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137-145.
18. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004;121:70-77.
19. Grushko TA, Blackwood MA, Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res. 2002;62:1481-1488.
20. Grushko TA, Dignam JJ, Das S, et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004;10:499-507.